Newssos
(NASDAQ: ICCM) shed 3.13% to $6.80 on June 26, even as the Caesarea, Israel-based cryoablation device maker carried a market capitalization of $572.57 million and a 52-week range spanning $2.12 to $42.
Benzinga named IceCure and Carbon Revolution PLC as equities its team would be closely watching.
IceCure Medical: Device Maker With a Wide Price Range Incorporated in 2006 and headquartered in Caesarea, Israel, IceCure Medical is a commercial-stage company that researches, develops and sells cryoablation systems — equipment that destroys tumors by freezing — across urology, oncology, dermatology, gynecology, general surgery, thoracic surgery and proctology.
Shares outstanding totaled 84.20 million against a total float of 47.60 million, a gap that leaves a material portion of the company outside freely traded hands.
Keep reading